OBJECTIVE: To systematically evaluate the efficacy and safety of colchicine for the prevention and treatment of pericarditis. METHODS: Retrieved from OVID, EMbase, SCI, CBM, CNKI, VIP, randomized controlled trials(RCTs)of colchicine for the prevention and treatment of pericarditis were included. Meta-analysis were carried out for homogeneity study using Rev-Man 5.0 software after systematical study selection, data extraction and quality evaluation. RESULTS: 5 RCTs were included, involving 795 patients. Meta-analysis indicated the differences of the incidence of the PPS[RR=0.44,95 %CI( 0.27,0.70) ,P=0.000 6] and the recurrence rate [RR=0.42,95%CI(0.29,0.60) ,P＜0.000 1] between groups were significant. There was no significant difference in the incidence of ADRs between 2 groups [RR=1.22, 95%CI(0.72, 2.07), P=0.47]. CONCLUSION: Based on routine treatment or routine treatment combined with aspirin, colchicine is safe and effective in the prevention and treatment of pericarditis.%目的:系统评价秋水仙碱预防和治疗心包炎的有效性及安全性.方法:计算机检索OVID、EMbase、SCI、中国生物医学文献数据库(CBM)、中国知网全文数据库(CNKI)、维普中文期刊数据库(VIP)等数据库,纳入秋水仙碱预防及治疗心包炎的随机对照试验.系统筛选文献、提取资料及评价质量后,对同质研究采用Rev Man 5.0软件进行Meta分析.结果:共纳入5项研究,795例患者.Meta分析结果显示,试验组与对照组心包切开术后综合征(PPS)发生率[RR=0.44,95％CI(0.27,0.70),P=0.0006]或心包炎复发率[RR=0.42,95％CI(0.29,0.60),P＜0.00001]差异均有统计学意义.2组不良反应发生率比较,差异无统计学意义[RR=1.22,95％CI(0.72,2.07),P=0.47].结论:在常规治疗或联合阿司匹林治疗的基础上,联用秋水仙碱能有效且安全地预防和治疗心包炎.
展开▼
